Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Deprescribing Olanzapine After Cancer-Related Symptoms Resolve: Insights From A Two-Case Series. Local targets link to admitted publications; unresolved targets remain external evidence.
Unresolved reference
2021 · External reference
Benefits and risks of off-label olanzapine use for symptom management in cancer patients—a case report
10.21037/apm-22-1167 · 2023 · External reference
Olanzapine-induced hypertriglyceridemia in cancer care: A silent metabolic risk
2025 · External reference
Cancer treatment and survivorship statistics, 2019
2019 · External reference
The Role of Professional Societies in Limiting Indication Creep
10.1007/s11606-014-2980-0 · 2015 · External reference
Antiemetic use of olanzapine in patients with advanced cancer: results from an open-label multicenter study
10.1007/s00520-018-4593-3 · 2019 · External reference
Olanzapine for Anorexia in Patients With Incurable Cancer and Cachexia (OlAnCa): A Double-Blind, Placebo-Controlled, Randomized Clinical Trial
10.6004/jnccn.2025.7033 · 2025 · External reference
Randomized Double-Blind Placebo-Controlled Study of Olanzapine for Chemotherapy-Related Anorexia in Patients With Locally Advanced or Metastatic Gastric, Hepatopancreaticobiliary, and Lung Cancer
10.1200/jco.22.01997 · 2023 · External reference
Unresolved reference
2015 · External reference
Novel Antipsychotics and Severe Hyperlipidemia
10.1097/00004714-200108000-00003 · 2001 · External reference
Long-term treatment with olanzapine in hospital conditions: Prevalence and predictors of the metabolic syndrome
10.2298/sarh1512712p · 2015 · External reference
10.2337/diacare.27.2.596
10.2337/diacare.27.2.596 · External reference
Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis
10.1016/s2215-0366(19)30416-x · 2020 · External reference
Can an early weight management program (WMP) prevent olanzapine (OLZ)-induced disturbances in body weight, blood glucose and lipid metabolism? Twenty-four- and 48-week results from a 6-month randomized trial
10.3109/15622975.2011.592546 · 2014 · External reference
Weight decline in patients switching from olanzapine to quetiapine
2004 · External reference
